PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Morrow, David A.
TI  - Evaluation of a Novel Antiplatelet Agent for Secondary Prevention in Patients with Atherosclerotic Disease: Results from the TRA 2P-TIMI 50 Trial
DP  - 2012 Jun 01
TA  - MD Conference Express
PG  - 19--19
VI  - 12
IP  - 4
4099  - http://mdc.sagepub.com/content/12/4/19.1.short
4100  - http://mdc.sagepub.com/content/12/4/19.1.full
AB  - In stable patients with a history of atherosclerosis, the investigational protease-activated receptor (PAR)-1 antagonist vorapaxar was effective at reducing further atherothrombotic events. This article presents data from the Thrombin Receptor Antagonist in Secondary Prevention-TIMI 50 Trial [TRA 2P; NCT00526474] which showed that vorapaxar significantly reduced the risk of deaths from cardiovascular disease, myocardial infarction, or stroke compared with placebo.